Vascular Biogenics Ltd expected to post a loss of 9cents a share - Earnings Preview

Notable Labs

21/03/2022 13:34

* Vascular Biogenics Ltd  VBLT.OQ   VBLT.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 23. 
    * The Modiin Israel-based   company is expected to report  a
3.9% decrease in revenue to $197 thousand from $205 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vascular Biogenics
Ltd is
for a loss of 9 cents per share. For the same quarter last year,
the company reported a loss of 15 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5.25​, above​ its last closing price of $1.46.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.11       -0.11      -0.09     Beat    16.3
 Jun. 30 2021  -0.11       -0.11      -0.12     Missed  -11.6
 Mar. 31 2021  -0.13       -0.13      -0.12     Beat    7.7​
 Dec. 31 2020              -0.14      -0.15     Missed  -7.1
 ​​Sep.        -0.14       -0.13      -0.12     Beat    10.2
 30 2020                                                
 Jun. 30 2020  -0.14       -0.14      -0.14     Met     -1.4​
 Mar. 31 2020  -0.17       -0.17      -0.15     Beat    9.4
 Dec. 31 2019  -0.13       -0.13      -0.16     Missed  -19.4
 This summary was machine generated March 21 at 13:33 GMT.  All
figures in US dollars  unless otherwise stated